(Q39404603)

11 September 2017

Orphan products--pain relief for clinical development headaches (English)

1 reference

11 September 2017

1 reference

Christopher-Paul Milne

series ordinal

1

1 reference

11 September 2017

1 August 2002

1 reference

11 September 2017

1 reference

11 September 2017

20

1 reference

11 September 2017

780-784

1 reference

11 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt0802-780

11 September 2017

0 references

cites work

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

BIOTECHNOLOGY:Disease Group Invests in Do-It-Yourself Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

The distribution of sales revenues from pharmaceutical innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

Growing pains for biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

7 January 2021

Understanding clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

7 January 2021

Realism in drug discovery-could Cassandra be right?

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

7 January 2021

Clinical Development of Therapeutic Medicines: A Biopharmaceutical versus Pharmaceutical Product Comparison

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

7 January 2021

Biotechnology. Disease group invests in do-it-yourself drugs

1 reference

https://api.crossref.org/works/10.1038%2FNBT0802-780

7 January 2021

Identifiers

DOI

10.1038/NBT0802-780

1 reference

11 September 2017

1 reference

PubMed ID

12148001